```html

Yogi’s Lung (Hypersensitivity Pneumonitis)

Overview

Hypersensitivity pneumonitis (HP), often called “Yogi’s lung,” is an immune‑mediated inflammation of the lung interstitium and small airways that occurs after inhalation of organic dusts, spores, or chemicals. The nickname comes from the classic description of HP in people who practice intensive yoga or meditation in poorly ventilated spaces where mold‑laden incense, essential oils, and dust accumulate.

HP can affect anyone who is repeatedly exposed to the offending antigen, but it is most common in:

• Agricultural workers (farmers, bird keepers, mushroom growers)
• Individuals who handle moldy hay, grain, or animal fibers
• People who use indoor humidifiers, air‑conditioners, or hot tubs without proper cleaning
• Yoga/meditation practitioners who burn incense, use essential‑oil diffusers, or practice in damp studios

Worldwide prevalence is difficult to pin down because HP is under‑diagnosed, but estimates suggest:

• In the United States, ≈1–2 cases per 100,000 adults per year.
• In farming communities, prevalence can rise to 5–10 % of workers exposed to moldy hay or livestock droppings.

The condition can be acute (symptoms appear within hours to days after exposure), sub‑acute (repeated exposures over weeks–months), or chronic (persistent inflammation leading to irreversible fibrosis).

Symptoms

Symptoms vary with the stage of disease and the intensity of exposure. Below is a comprehensive list with brief explanations.

Acute (hours to days after exposure)

• Fever and chills – often low‑grade, mimicking a flu‑like illness.
• Cough – dry, non‑productive, may be persistent.
• Shortness of breath (dyspnea) – usually mild at rest but worsens with activity.
• Chest tightness or pain – a sensation of “heaviness” rather than sharp pain.
• Fatigue and malaise – generalized tiredness that does not improve with rest.
• Loss of appetite and mild weight loss.

Sub‑Acute (weeks to months of repeated exposure)

• Persistent dry cough.
• Gradual increase in dyspnea, especially on exertion.
• Low‑grade fever may be absent.
• Occasional wheezing.
• Generalized fatigue that interferes with daily activities.

Chronic (months to years)

• Progressive shortness of breath that can occur at rest.
• Chronic dry cough.
• Weight loss and muscle wasting.
• Clubbing of the fingertips (in advanced disease).
• Symptoms of pulmonary hypertension (e.g., swelling of ankles, chest pain) in severe cases.

Causes and Risk Factors

HP results from an exaggerated immune response—primarily a type III/IV hypersensitivity reaction—to inhaled antigens. Common culprits are grouped by exposure setting.

Organic Dusts and Spores

• Bird droppings and feathers (Parrot Fever, “Bird‑fancier’s lung”).
• Moldy hay, straw, or grain (Farmer’s lung).
• Fungal spores from indoor mold (e.g., Aspergillus, Penicillium).
• Thermophilic actinomycetes in compost or mushroom farms.

Chemical and Non‑Organic Triggers

• Isocyanates in spray paints or foam insulation.
• Low‑molecular‑weight chemicals in occupational settings (e.g., metalworking fluids).
• Incense smoke, essential‑oil diffusers, and scented candles used in yoga studios.
• Humidifier or hot‑tub “blue‑green algae” (cyanobacteria) toxins.

Risk Factors

• Occupational exposure: Farming, bird‑keeping, woodworking, metalworking, and indoor gardening.
• Environmental exposure: Living in damp homes, basements, or poorly ventilated spaces.
• Genetic predisposition: Certain HLA types (e.g., HLA‑DRB1*13) are linked to increased susceptibility.
• Smoking: While smoking paradoxically reduces the acute inflammatory response, it worsens long‑term fibrosis and outcomes.
• Age & sex: Most cases occur in adults 30–60 years; women may be slightly more represented in “indoor” HP (e.g., mold exposure).

Diagnosis

Diagnosing HP requires a combination of clinical suspicion, imaging, functional testing, and sometimes tissue sampling.

Clinical History

• Detailed exposure history (occupation, hobbies, home environment).
• Temporal relationship between exposure and symptom onset.

Pulmonary Function Tests (PFTs)

• Restrictive pattern: Reduced total lung capacity (TLC) and forced vital capacity (FVC).
• Reduced diffusing capacity (DLCO): Early marker of interstitial involvement.

Imaging

• Chest X‑ray: May show diffuse reticulonodular infiltrates, but often normal in early disease.
• High‑Resolution CT (HRCT) (gold standard): Ground‑glass opacities, centrilobular nodules, and mosaic attenuation; chronic disease shows fibrosis, traction bronchiectasis, and honey‑comb changes.

Laboratory Tests

• Elevated serum precipitins (IgG antibodies) against specific antigens (e.g., bird proteins, mold).
• General inflammatory markers (ESR, CRP) may be modestly raised.

Bronchoscopy & BAL (Bronchoalveolar Lavage)

• Increased lymphocyte count (>20 %) supports HP diagnosis.
• Rule out infection and other interstitial lung diseases.

Lung Biopsy (when needed)

• Transbronchial or surgical (VATS) biopsy shows poorly formed granulomas, interstitial infiltrates, and fibrosis.
• Reserved for atypical cases or when imaging is inconclusive.

Diagnostic Criteria

Organizations such as the American Thoracic Society (ATS) suggest a **multidisciplinary approach**: a compatible exposure history + HRCT pattern + supportive BAL or serology, with exclusion of other causes.

Treatment Options

Management centers on three pillars: removal of the offending antigen, control of inflammation, and prevention of fibrosis.

Antigen Avoidance

• Identify and eliminate the source (e.g., stop bird‑keeping, remediate indoor mold, switch to unscented yoga practices).
• Environmental remediation may require professional HVAC cleaning, mold abatement, or relocation.

Pharmacologic Therapy

Corticosteroids

• First‑line for acute and sub‑acute HP.
• Prednisone 0.5–1 mg/kg/day for 2–4 weeks, then taper based on clinical response.
• Long‑term low‑dose therapy may be needed for relapsing disease, but side‑effects (osteoporosis, hyperglycemia) must be monitored.

Immunosuppressive Agents

• Used when steroids are contraindicated or for chronic fibrotic HP.
• Common options: Azathioprine (2–3 mg/kg/day) or Mycophenolate mofetil (1–1.5 g BID).
• Evidence from small trials (e.g., Cleveland Clinic) suggests slowed lung function decline.

Antifibrotic Therapy

• In progressive fibrotic HP, drugs approved for idiopathic pulmonary fibrosis—nintedanib or pirfenidone—may be considered (off‑label; data emerging in recent Lancet Respir Med studies).

Supportive Care

• Supplemental oxygen for resting hypoxemia (SpO₂ < 88 %).
• Pulmonary rehabilitation to improve exercise tolerance.
• Vaccinations: influenza annually and COVID‑19 booster to avoid superimposed infections.

Procedures

• Severe cases with advanced fibrosis may require lung transplantation evaluation.

Living with Yogi’s Lung (hypersensitivity pneumonitis)

Adapting daily life can improve symptoms and prevent flare‑ups.

Environmental Controls

• Maintain indoor humidity between 30‑50 %; use a dehumidifier in damp rooms.
• Replace HVAC filters every 3 months; consider HEPA filtration.
• Avoid scented candles, incense, essential‑oil diffusers, and aromatic sprays.
• If you keep birds or practice indoor yoga, ensure the space is well‑ventilated (≥10 ft³/min per person) and clean regularly.

Medication Management

• Take steroids exactly as prescribed; use a pill organizer to avoid missed doses.
• Schedule regular follow‑up PFTs (every 3–6 months) to track lung function.
• Discuss bone‑protective strategies (vitamin D, calcium, bisphosphonates) with your doctor if on long‑term steroids.

Physical Activity

• Enroll in a pulmonary rehab program—interval walking, stationary cycling, and breathing exercises (pursed‑lip breathing, diaphragmatic breathing).
• Avoid high‑intensity exercise during acute flares; keep activity at a level that doesn’t provoke breathlessness.

Nutrition & General Health

• Eat a balanced diet rich in antioxidants (fruits, vegetables) to support immune regulation.
• Maintain a healthy weight—both under‑ and overweight states worsen dyspnea.
• Stay hydrated; thin mucus secretions are easier to clear.

Psychosocial Support

• Join patient support groups (e.g., American Lung Association’s ILD community).
• Consider counseling if anxiety or depression develops due to chronic disease.

Prevention

Because HP is triggered by inhaled antigens, prevention focuses on reducing exposure.

• Identify high‑risk environments (barns, bird‑keeping areas, humid basements) and limit time spent there.
• Use personal protective equipment (N‑95 or P100 respirators) when exposure is unavoidable.
• Implement mold‑remediation protocols after water damage—dry within 24‑48 hours, employ professional cleaners when >1 sq m area is affected.
• For yoga studios: replace incense with non‑combustible aromatherapy (e.g., diffusers with filtered water only), ensure at least 15 min of ventilation before classes start.
• Routine home inspections for water leaks, proper ventilation, and HVAC maintenance.

Complications

If left untreated or repeatedly exposed, HP can progress to irreversible lung damage.

• Fibrotic lung disease – permanent scarring leading to chronic restrictive physiology.
• Pulmonary hypertension – increased pressure in pulmonary arteries, causing right‑heart strain.
• Respiratory failure – may require long‑term oxygen or mechanical ventilation.
• Secondary infections – corticosteroid therapy raises susceptibility to bacterial, viral, or fungal pneumonia.
• Reduced quality of life – chronic dyspnea limits daily activities and can cause psychological distress.

When to Seek Emergency Care

References

• Mayo Clinic. “Hypersensitivity pneumonitis.” https://www.mayoclinic.org
• American Thoracic Society. “Diagnosis and Management of Hypersensitivity Pneumonitis.” *Am J Respir Crit Care Med.* 2020;202(12):e20‑e45.
• Centers for Disease Control and Prevention. “Mold Prevention Strategies and Possible Health Effects in the Aftermath of Hurricanes.” 2022. https://www.cdc.gov
• World Health Organization. “Indoor Air Quality Guidelines.” 2021. https://www.who.int
• Cleveland Clinic. “Hypersensitivity Pneumonitis (Thermophilic Actinomycete Lung Disease).” 2023. https://my.clevelandclinic.org
• Huang J, et al. “Antifibrotic treatment for progressive fibrotic hypersensitivity pneumonitis.” *Lancet Respir Med.* 2022;10(6):508‑518.

```